Biohaven’s drug for genetic neurological disease fails late-stage study
By Syndicated ContentMay 23, 2022 | 7:28 AM
(Reuters) – Biohaven Pharmaceutical said on Monday a late-stage trial of its drug against a genetic neurological disease failed to meet the primary goal of the study.
(Reporting by Leroy Leo in Bengaluru; Editing by Aditya Soni)
For the health and safety of everyone, our offices are temporarily closed to the public. If you have won a prize from us we will be mailing it to you or will contact you with specific information needed to redeem your prize. Feel free to call us with questions during weekday business hours at (616) 392-3121.
